Skip to main content

Business

By Jessica Hagen | 03:57 pm | February 12, 2026
The funding will help the company scale its AI-powered, in-network virtual psychiatry platform, which employs more than 800 full-time psychiatrists.
By Jessica Hagen | 12:02 pm | February 12, 2026
The doctor quality analytics company's total funding to date is around $200 million.
Emerging Technologies
By HIMSS TV | 09:47 am | February 12, 2026
Dr. Amit Zabtani, an orthopedic surgeon at UCLA and cofounder and CMO of CustoMED, says the company uses 3D printing to create patient-specific instruments based on an individual’s anatomy, enabling more precise positioning during surgery.
By Jessica Hagen | 10:20 am | February 11, 2026
New York-based Somethings will use the funds to scale its mobile app that connects teens and young adults with trained peer mentors.
By HIMSS TV | 10:09 am | February 11, 2026
According to Clearwater's Jackie Mattingly, sustainable cybersecurity funding for rural hospitals remains elusive, with many states allocating little to no Rural Health Transformation Program money to security.
By Jessica Hagen | 01:44 pm | February 10, 2026
The California-based company will use the funds to expand its healthcare advocate network and platform, partnerships with payers and providers and for clinical research.
Emerging Technologies
By Jessica Hagen | 12:21 pm | February 10, 2026
Debra Beauregard, director of medical intelligence and innovation at San Diego-based Rady Children's Health, joins MobiHealthNews to discuss partnering with digital health companies.
Emerging Technologies
By HIMSS TV | 10:01 am | February 10, 2026
Debra Beauregard, director of medical intelligence and innovation at Rady Children’s Health, discusses why some hospitals are cautious about exploring new technologies and how her team evaluates technology solutions to pilot and scale.
By Jessica Hagen | 04:33 pm | February 09, 2026
The company will use the funds to advance its brain shuttle platform that delivers RNAi therapies across the blood-brain barrier to help treat neurodegenerative diseases.
By Jessica Hagen | 01:40 pm | February 09, 2026
The pharma giant alleges that Hims & Hers is infringing its patents and misleading consumers by selling unsafe, unapproved compounded versions of its semaglutide drugs.